• Elizabeth M Viglianti, Sean M Bagshaw, Rinaldo Bellomo, Joanne McPeake, Daniel J Molling, Xiao Qing Wang, Sarah Seelye, and Theodore J Iwashyna.
• Department of Internal Medicine Division of Pulmonary and Critical Care, University of Michigan, Ann Arbor, MI. Electronic address: eviglian@med.umich.edu.
• Chest. 2020 Aug 1; 158 (2): 571578571-578.

BackgroundLittle is known about the prevalence, predictors, and outcomes of late vasopressor administration which evolves after admission to the ICU.Research QuestionWhat is the epidemiology of late vasopressor administration in the ICU?Study Design And MethodsWe retrospectively studied a cohort of veterans admitted to the Veterans Administration ICUs for ≥ 4 days from 2014 to 2017. The timing of vasopressor administration was categorized as early (only within the initial 3 days), late (on day 4 or later and none on day 3), and continuous (within the initial 2 days through at least day 4). Regressions were performed to identify patient factors associated with late vasopressor administration and the timing of vasopressor administration with posthospitalization discharge mortality.ResultsAmong the 62,206 hospitalizations with at least 4 ICU days, late vasopressor administration occurred in 5.5% (3,429 of 62,206). Patients with more comorbidities (adjusted OR [aOR], 1.02 per van Walraven point; 95% CI, 1.02-1.03) and worse severity of illness on admission (aOR, 1.01 per percentage point risk of death; 95% CI, 1.01-1.02) were more likely to receive late vasopressor therapy. Nearly 50% of patients started a new antibiotic within 24 h of receiving late vasopressor therapy. One-year mortality after survival to discharge was higher for patients with continuous (adjusted hazard ratio [aHR], 1.48; 95% CI, 1.33-1.65) and late vasopressor administration (aHR, 1.26; 95% CI, 1.15-1.38) compared with only early vasopressor administration.InterpretationLate vasopressor administration was modestly associated with comorbidities and admission illness severity. One-year mortality was higher among those who received late vasopressor administration compared with only early vasopressor administration. Research to understand optimization of late vasopressor therapy administration may improve long-term mortality.Copyright © 2020 American College of Chest Physicians. All rights reserved.

19 keywords...

hide…